Rigel Pharmaceuticals secured a global licensing agreement for vepdegestrant (marketed as Veppanu) after Pfizer and Arvinas reduced their exposure to the estrogen-receptor bifunctional degrader. The arrangement follows U.S. FDA approval earlier in the month, making Veppanu the first bifunctional degrader to reach that milestone. The deal structure shifts commercialization and future milestone dependence to Rigel, while Pfizer and Arvinas recouped value through the out-licensing. Industry follows vepdegestrant closely as the category’s first U.S. test of whether bifunctional degradation can deliver clear differentiation versus established endocrine standards. For sponsors, the transaction underscores the commercial math driving targeted-degradation partnerships—especially when late-stage results don’t clearly outperform existing options.